1. Home
  2. UROY vs RIGL Comparison

UROY vs RIGL Comparison

Compare UROY & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UROY
  • RIGL
  • Stock Information
  • Founded
  • UROY 2017
  • RIGL 1996
  • Country
  • UROY Canada
  • RIGL United States
  • Employees
  • UROY N/A
  • RIGL N/A
  • Industry
  • UROY
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • UROY
  • RIGL Health Care
  • Exchange
  • UROY Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • UROY 336.8M
  • RIGL 335.5M
  • IPO Year
  • UROY N/A
  • RIGL 2000
  • Fundamental
  • Price
  • UROY $3.15
  • RIGL $38.85
  • Analyst Decision
  • UROY Strong Buy
  • RIGL Buy
  • Analyst Count
  • UROY 2
  • RIGL 5
  • Target Price
  • UROY $4.00
  • RIGL $38.20
  • AVG Volume (30 Days)
  • UROY 2.6M
  • RIGL 995.6K
  • Earning Date
  • UROY 07-16-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • UROY N/A
  • RIGL N/A
  • EPS Growth
  • UROY N/A
  • RIGL N/A
  • EPS
  • UROY N/A
  • RIGL 5.43
  • Revenue
  • UROY $11,285,840.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • UROY $228.36
  • RIGL $59.93
  • Revenue Next Year
  • UROY N/A
  • RIGL N/A
  • P/E Ratio
  • UROY N/A
  • RIGL $7.15
  • Revenue Growth
  • UROY N/A
  • RIGL 105.62
  • 52 Week Low
  • UROY $1.43
  • RIGL $12.66
  • 52 Week High
  • UROY $3.30
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • UROY 65.88
  • RIGL 68.57
  • Support Level
  • UROY $2.51
  • RIGL $39.00
  • Resistance Level
  • UROY $2.87
  • RIGL $42.08
  • Average True Range (ATR)
  • UROY 0.16
  • RIGL 2.32
  • MACD
  • UROY 0.05
  • RIGL -0.37
  • Stochastic Oscillator
  • UROY 82.05
  • RIGL 53.26

About UROY Uranium Royalty Corp.

Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: